NCT00185172

Olmesartan in Essential Hypertension

Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,333 (actual)
• Sponsor: Sankyo Pharma Gmbh · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To test the efficacy and safety of olmesartan in patients with essential hypertension.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
OTHER	placebo	Placebo oral tablets for 2 weeks
DRUG	olmesartan medoxomil	olmesartan medoxomil oral tablets for 8 weeks
DRUG	olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets	olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets

Timeline

• Start date: 2002-01-01
• Primary completion: 2005-06-01
• Completion: 2005-06-01
• First posted: 2005-09-16
• Last updated: 2008-04-29

Locations

8 sites across 8 countries: Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom